NBP
NovaBridge Biosciences
NASDAQ · USHealthcareBiotechnology
$1.79+0.56%
Price as of Jul 20, 2026
NBP financials
NovaBridge Biosciences financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $4.5M | -$10.7M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $4.5M | -$10.7M |
| Operating expenses | $13.5M | $375.4M | $515.6M | $355.4M |
| Operating income | -$13.5M | -$375.4M | -$511.2M | -$366.1M |
| Net income | -$6.6M | -$162.3M | -$1.5B | -$967.5M |
| EBITDA | -$13.4M | -$373.5M | -$344.3M | -$356.4M |
| Basic EPS | $-0.16 | $-4.46 | $-17.62 | $-30.38 |
| Diluted EPS | $-0.16 | $-4.46 | $-17.62 | $-30.38 |
| Balance sheet | ||||
| Cash & equivalents | $30.1M | $498.2M | $291.5M | $3.2B |
| Total assets | $37.2M | $1.6B | $368.9M | $4.1B |
| Total liabilities | $4.2M | $84.1M | $126.3M | $1.1B |
| Stockholders’ equity | $33.0M | $1.5B | $242.6M | $3.0B |
| Total debt | $438.5K | $28.3M | $3.9M | $38.3M |
| Net debt | -$29.7M | -$469.9M | -$287.6M | -$3.2B |
| Cash flow | ||||
| Operating cash flow | -$20.6M | -$384.3M | -$72.9M | -$1.1B |
| Capital expenditure | -$7.0K | -$350.3K | -$164.4K | -$45.8M |
| Free cash flow | -$20.6M | -$384.8M | -$73.0M | -$1.1B |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | -$2.4M | -$8.7M | -$3.1M |